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infection
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Abstract
The detection of hepatitis C virus (HCV)-specific T cell responses in HCV-uninfected, presumably unexposed,
subjects could be due to an underestimation of the frequency of spontaneously resolving infections, as most acute
HCV infections are clinically silent. To address this hypothesis, HCV-specific cellular immune responses were
characterized, in individuals negative for an HCV PCR assay and humoral response, with (n = 32) or without (n =
33) risk of exposure to HCV. Uninfected volunteers (n = 20) with a chronically HCV-infected partner were included
as positive controls for potential exposure to HCV and HCV infection, respectively. HCV-specific T cell responses in
freshly isolated peripheral blood mononuclear cells were studied ex vivo by ELISPOT and CFSE-based proliferation
assays using panels of HCV Core and NS3-derived peptides. A pool of unrelated peptides was used as a negative
control, and a peptide mix of human cytomegalovirus, Epstein-Bar virus and Influenza virus as a positive control.
Overall, 20% of presumably HCV-uninfected subject tested had detectable T-cell responses to the virus, a rate
much higher than previous estimates of HCV prevalence in developed countries. This result would be consistent
with unapparent primary HCV infections that either cleared spontaneously or remained undetected by
conventional serological assays.
Keywords: HCV, Prevalence, Proliferation, Elispot, Inapparent infection
Background
Hepatitis C virus (HCV) is a positive stranded RNA virus
belonging to the Flaviviridæ family. HCV replicates
mainly in the liver, and approximately 70% of infected
persons fail to spontaneously clear the virus, progressing
to chronic infection. HCV infection is defined as the
detection of specific antibodies in the serum (by two dif-
ferent screening assays), with or without detectable
HCV-specific RNA which reflects ongoing or resolved
infection, respectively. An estimated 170 million persons
worldwide are infected by HCV.
Three sets of data challenge current estimates of the
proportion of HCV-infected patients that become
chronic carriers [1]. Firstly, HCV-specific T lymphocytes
are found in the blood of donors who do not meet
current criteria for HCV infection, displaying a weak or
restricted specific antibody response labeled as an ‘inde-
terminate pattern’ in the recombinant immunoblot con-
firmation assay [2]. Secondly, the clearance of HCV has
been reported in individuals without detectable serocon-
version [3]. Thirdly, the disappearance of circulating anti-
HCV antibodies some two decades after an accidental
inoculation has been documented in patients who spon-
taneously resolve their infection, although HCV-specific
CD4+ and CD8+ T-cell responses were detectable [4].
Thus, as most acute HCV infections are clinically
silent, the detection of a virus-specific T cell response in
healthy presumably unexposed subjects who do not meet
current criteria for a previous HCV infection can be due
to preceding silent spontaneously resolved HCV infec-
tion, the frequency of which is apparently underestimated
[5,6]. Viral infection in such individuals would have pro-
duced enough viral immunogen to prime T cells, but yet
not enough to prime an IgG B cell response that could
* Correspondence: yves.riviere@pasteur.fr
1Laboratoire d’Immunopathologie Virale, Institut Pasteur; and CNRS URA
3015, 25 rue du Dr Roux, 75015 Paris, France
Full list of author information is available at the end of the article
Rivière et al. Virology Journal 2012, 9:76
http://www.virologyj.com/content/9/1/76
© 2012 Rivière et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
be detected by the available commercial assays [3,7]. If
confirmed, such an hypothesis could change our views
concerning the epidemiology and physiopathology of
HCV infections. An alternative hypothesis could be the
existence of T cell epitope cross-reactivity between other
pathogens or common antigens present in the general
population and HCV as previously reported [8-10]. These
two hypotheses are not mutually exclusive.
To investigate such possibilities, HCV-specific cellular
immune responses were characterized in uninfected
individuals (UI) where neither the presence of HCV
RNA nor that of anti-HCV antibody had previously
been detected. Exposed uninfected volunteers (EUI) and
their chronically HCV-infected (CI) sexual partners were
included in this study as positive controls for HCV
exposure and infection, respectively.
Results
We assembled three cohorts of individuals that differed
in their history with respect to potential exposure to
HCV, and HCV infection. The first group comprised
apparently noninfected, nonexposed volunteers (UI),
although about half of these were at risk of exposure to
the virus. Exclusion factors for exposure to HCV [11]
were: professional exposure, drug abuse, blood transfu-
sion or injection of blood products, sexually transmitted
diseases, incarceration, alcoholism, dialysis, endoscopy,
acupuncture, mesotherapy, invasive cosmetic treatment,
piercing, tattooing, sexual exposure, familial exposure,
and hospitalization or outpatient treatment in a develop-
ing country. A second group consisted of individuals who
remained uninfected despite repeated exposure (EUI),
who were in fact exposed through their sexual contact
with a member of the third group: their long-standing
chronically-infected (CI) partners.
HCV-specific responses
Proliferative responses
HCV-specific proliferative T cell responses were tested
in 62 of the 65 uninfected volunteers (UI). Among
these, 2 were positive for Core, and 4 for NS3 (Table 1).
The response directed against Core involved both CD4
and CD8 populations for volunteer EFS20 who had no
known risk of HCV exposure (Figure 1, panels A & B,
and Table 2), and a CD4 population for EFS 11 (at risk)
(Table 3). For NS3, a response involved the CD4 popu-
lation (COC 13, Table 2, and EFS14, Table 3), the CD8
population (EFS 21, Table 3) or both CD4 and CD8
populations (EFS 24, Table 3). All three EFS donors
were at risk of HCV exposure, in contrast to risk-free
volunteer COC 13. None of the supposedly uninfected
(UI) volunteers was found to be positive for both NS3
and Core.
In the group of chronically infected patients (CI) 17
patients were tested (Table 1), and three showed a
Core-specific response: one (CIC 34) involving the CD8
population and two (CIC 38, 46) the CD4 population
(Table 4, and Figure 2, panel A). For NS3, 2/16 patients
were positive: one involving CD8 cells (CIC18), and one
CD4 (CIC 38) (Table 4, and Figure 2 panel C). Thus
one patient (CIC 38) was positive for both NS3 and
Core, in both cases the response involving the CD4
population.
None of the 17 exposed but uninfected (EUI) volun-
teers was positive for either Core or NS3 (Table 1).
No statistical difference was found in the frequencies
of proliferative responses to both HCV antigens in pair-
wise comparisons of all groups (t-test for independent
samples; all p’s > 0.05) (Table 1).
Elispot responses
The same antigens were used in Elispot assays to assess
the occurrence/frequency of HCV-specific circulating
effector T lymphocyte responses. Eight of 65 uninfected
(UI) volunteers tested were positive for Core, and none
for NS3 (Table 1). Four of the 8 volunteers that gave a
positive Core response were at risk (CIC 05, 22, 55, 59;
Table 3), and 4 were without any known risk for HCV
exposure (CIC 16 and 17, COC 17, and EFS 20; Table
2). This last donor was also positive in the proliferation
test (see above).
Table 1 Proliferative and Elispot responses in chronically HCV-infected, exposed and uninfected volunteers
PROLIFERATION ELISPOT
VOLUNTEERS CORE NS3 CEF CORE NS3 CEF
All 2/61 (3)4 4/62 (6) 24/62 (39) 8/65 (12) 0/59 (0) 31/58 (53)
UI1 No risk 1/29 (3) 1/30 (3) 10/30 (33) 4/33 (12) 0/29 (0) 13/28 (46)
At risk 1/32 (3) 3/32 (9) 14/32 (44) 4/32 (13) 0/30 (0) 18/30 (60)
EUI2 0/17 (0) 0/17 (0) 5/17 (29) 6/20 (30) 1/11 (9) 6/11 (55)
CI3 3/17 (18) 2/16 (12,5) 9/16 (56) 8/20 (40) 2/6 (33) 3/6 (50)
1: Uninfected individuals (UI); 2: Exposed uninfected partners (EUI) of, 3: chronically HCV-infected (CI) individuals. 4: number positive/total number tested
(percent). Control antigen (CEF) : There were no statistical difference in the frequencies of proliferative or elispot responses to CEF when comparing each group 2
by 2. HCV antigens : There were no statistical difference in the frequencies of proliferative response to both Core and NS3 when comparing each group 2 by 2;
The frequencies of Elispot response to Core were higher in the CI group compared to UI no risk (p = 0.04) and to UI at risk (p = 0.04). The frequencies of Elispot
response to NS3 were higher in the CI group compared to UI no risk (p < 0.03) and to UI at risk (p < 0.03).
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Figure 1 example of proliferation for PBMC of volunteer EFS 20. Dot-plots show the percentage of proliferative CD8 + (FL1/FL4) or CD4 +
(FL1/FL5) - T cells. The number in the upper left panel stands for the percentage of CD4+ or CD8+ proliferative cells among the total CD4+ or
CD8+ -T lymphocyte population, respectively, in the absence (DMSO) or the presence of Core or CEF antigens. The positive responses are in bold
characters.
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All 20 chronically-infected (CI) subjects were tested
for IFN-g production in response to Core, and six for
IFN-g production in response to NS3 (Table 1). Eight
presented a Core-specific response (CIC 2, 18, 25, 31-
32, 40, 46, 64) and two NS3-specific IFN-g response
(CIC 18 and 40). Thus 2 individuals (CIC 18 and 40)
demonstrated IFN-g production in response to both
viral proteins tested (Tables 1 and 4).
Six of 20 exposed but uninfected (EUI) partners
demonstrated IFN-g production in response to Core
(CIC 24, 28, 30, 37, 41 and 45), and 1 of 11 tested an
IFN-g response to NS3 (CIC 43); none responded to
both viral antigens (Tables 1 and 4).
Table 2 Responses in uninfected volunteers with no
known risk of exposure to HCV
I.D Sex Proliferation* Elispot**
Core NS3 CEF Core NS3 CEF
CIC 09 F (-) (-) (-) (-) (-) 15
CIC 16 M (-) (-) (-) 24 bgd bgd
CIC 17 M ND ND ND 9 ND ND
CIC 23 M ND ND ND (-) ND ND
CIC 53 M (-) (-) (-) (-) (-) (-)
EFS 04 F (-) (-) 6 (T8) (-) (-) 252
EFS 05 F (-) (-) (-) (-) (-) (-)
EFS 08 F bgd bgd bgd (-) (-) (-)
EFS 10 F (-) (-) 7 (T8) (-) (-) (-)
EFS 16 M (-) (-) bgd (-) (-) 17
EFS 18 F (-) (-) (-) (-) (-) (-)
EFS 20 F 9 (T8), 16(T4) (-) 19 (T8) 18 (-) 9
EFS 22 F (-) (-) (-) (-) (-) 8
COC 01 M ND ND ND (-) (-) ND
COC 02 F (-) (-) (-) (-) (-) (-)
COC 03 F (-) (-) (-) (-) ND ND
COC 04 M (-) (-) 14 (T8) (-) (-) 9
COC 05 M (-) (-) (-) (-) (-) (-)
COC 06 M (-) (-) (-) (-) (-) 16
COC 07 M (-), bgd (-), bgd 20 (T8) (-) (-) 20
COC 08 F (-) (-) 5 (T8) (-) (-) (-)
COC 09 F (-), bgd (-), bgd 16 (T8) (-) (-) 24
COC 10 M (-) (-), bgd (-) (-) (-) 34
COC 11 M (-) (-) (-) (-) (-) (-)
COC 12 F (-) (-), bgd (-) (-) (-) (-)
COC 13 F (-) 7 (T4) 16 (T8) (-) (-) 13
COC 14 M (-) (-) (-) (-) (-) (-)
COC 15 F (-) (-) (-) (-) (-) (-)
COC 16 M ND (-) (-) (-) ND ND
COC 17 M (-), bgd (-), bgd 14 (T8), bgd 6 (-) 5
COC 18 F (-), bgd (-), bgd (-) (-) (-) (-)
COC 19 M (-) (-) (-) (-) (-) 1087
COC 20 M (-) (-) 5(T8) (-) (-) (-)
* (-) = absence, or xx = presence of antigen-specific proliferation. (T4) or (T8)
stands for the nature of the proliferating lymphocyte population, and the
number for specific antigen to control antigen ratio. The CEF panel of EBV,
CMV and Flu peptides is described in ref 12.
** (-) = no antigen specific ELISPOT; xx = presence of antigen specific ELISPOT
response. The number stands for specific antigen to control ratio.
Abbreviations: bgd background level in absence of antigen; ND not
determined.
Table 3 Responses in uninfected volunteers at risk for
exposure to HCV
I.D Sex Proliferation* Elispot**
Core NS3 CEF Core NS3 CEF
CIC 03 F (-), bgd (-), bgd (-), bgd (-) (-) 38
CIC 04 F (-) (-) 5(T8) (-) (-) (-)
CIC 05 F (-), bgd (-), bgd 43(T8), bgd 25 (-) 572
CIC 06 F (-) (-) (-) (-) (-) (-)
CIC 07 M (-), bgd (-), bgd (-), bgd (-) (-) (-)
CIC 08 F (-) (-) 47(T8) (-) (-) 47
CIC 20 M bgd bgd bgd (-) (-) (-)
CIC 22 M (-) (-) 18 (T8) 344 ND ND
CIC 50 M (-) (-) (-) (-) (-) (-)
CIC 54 F (-) (-) 306(T8) (-) (-) (-)
CIC 55 M (-) (-) (-) 27 (-) 10
CIC 58 F (-) (-) (-) (-) (-) (-)
CIC 59 M (-) (-) (-) 39 ND ND
CIC 62 F (-) (-) (-) (-) (-) 429
CIC 63 F (-) (-) (-) (-) (-) 13
EFS 01 F (-) (-) (-) (-) (-) 33
EFS 02 M (-) (-) (-) (-) (-) 7
EFS 03 F (-) (-) (-) (-) (-) (-)
EFS 06 F (-) (-) 120(T8) (-) (-) 44
EFS 07 F (-) (-) (-) (-) (-) (-)
EFS 09 F (-) (-) 8(T8) (-) (-) 6
EFS 11 F 7(T4) (-) 5(T8) (-) (-) 29
EFS 12 F (-) (-) 110(T8),11(T4) (-) bgd bgd
EFS 13 F (-) (-) (-) (-) (-) (-)
EFS 14 F (-) 10(T4) 8(T8) (-) (-) 178
EFS 15 F (-) (-) (-) (-) (-) 28
EFS 17 F (-) (-) 5(T8) (-) (-) 63
EFS 19 M (-) (-) 15(T8) (-) (-) 76
EFS 21 F (-) 7(T8) 21(T8) (-) (-) (-)
EFS 23 F (-), bgd (-), bgd (-), bgd (-) (-) 7
EFS 24 F (-) 6(T8), 7(T4) 9(T8) (-) (-) 20
EFS 25 F (-) (-) (-) (-) (-) 32
* (-) = absence, or xx = presence of antigen-specific proliferation. (T4) or (T8)
stands for the nature of the proliferating lymphocyte population, and the
number for specific antigen to control antigen ratio. The CEF panel of EBV,
CMV and Flu peptides is described in ref 12.
** (-) = no antigen specific ELISPOT; xx = presence of antigen specific ELISPOT
response. The number stands for specific antigen to control ratio.
Abbreviations: bgd background level in absence of antigen; ND not
determined.
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Table 4 Characteristics of the 20 pairs of chronically HVC infected patients and their exposed uninfected partners
I.D* Sex HCV infection** Proliferation*** Elispot****
Viral load Genotype Duration Mode Core NS3 CEF Core NS3 CEF
CI CIC 02 F 354 000 1b 22 Blood T (-) (-) 143(T8) 10 ND ND
EUI CIC 01 M - - - - (-), bgd (-), bdg 10(T8), bgd (-) (-) 4
CI CIC 10 F 20 000 4 ND Unknown (-) (-) 18(T8) (-) (-) 6
EUI CIC 11 M - - - - ND ND ND (-) bgd bgd
CI CIC 12 F 210 000 4c/b 15 Surgery bgd bgd bgd (-) ND ND
EUI CIC 13 M - - - - (-), bgd (-), bgd 5(T8), bgd (-) (-) 16
CI CIC 14 F 1 850 000 1a 24 IVDU (-) (-) 11(T8) (-) ND ND
EUI CIC 15 M - - ND ND ND (-) (-) 13
CI CIC 18 F 380 000 3 24 IVDU (-) 76 (T8) (-) 21 295 (-)
EUI CIC 19 M - - - - (-) (-) (-) (-) (-) (-)
CI CIC 25 M 1 300 000 1b 23 tattooing (-) ND ND 4 ND ND
EUI CIC 24 F - - - - (-) (-) 83(T8) 12 ND ND
CI CIC 26 M 215 000 1b 16 Blood T (-) (-) 11(T8) (-) ND ND
EUI CIC 27 F - - - - (-), bgd (-), bgd (-), bgd (-) ND ND
CI CIC 29 F 30 000 ND ND Unknown bgd bgd bgd (-) (-) (-)
EUI CIC 28 M - - - - (-) (-) 37(T8) 7 bgd bgd
CI CIC 31 M 200 000 1b 37 Blood T ND ND ND 8 ND ND
EUI CIC 30 F - - - - (-) (-) 9(T8) 55 (-) 45
CI CIC 32 M 1 425 000 1b ND Unknown (-) (-) (-) 10 ND ND
EUI CIC 33 F - - - - (-) (-) (-) (-) ND ND
CI CIC 34 M 100 000 1b 16 Blood T 14(T8) (-) (-) (-) ND ND
EUI CIC 35 F - - - - (-) (-) (-) (-) (-) 89
CI CIC 36 F 35 000 3a ND Unknown (-) (-) 29(T8) (-) ND ND
EUI CIC 37 M - - - - (-) (-) (-) 12 (-) 72
CI CIC 38 F 260 000 1a 43 Blood T 7(T4) 4(T4) 433(T8) (-) ND ND
EUI CIC 39 M - - - - (-) (-) (-) (-) ND ND
CI CIC 40 M 332 000 1a 16 Blood T (-) (-) 10(T8) 19 8 100
EUI CIC 41 F - - - - (-) (-) (-) 10 ND ND
CI CIC 42 F 140 000 1b 20 Blood T (-) (-) (-) (-) (-) (-)
EUI CIC 43 M - - - - (-) (-) (-) (-) 7 (-)
CI CIC 44 F 82 000 1b 22 Blood T ND ND ND (-) ND ND
EUI CIC 45 M - - - - (-) (-) (-) 11 (-) (-)
CI CIC 46 M 2 200 000 1b 25 Blood T 6(T4) (-) 434(T8) 10 (-) 2070
EUI CIC 47 F - - - - (-) (-) (-) (-) ND ND
CI CIC 51 M 180 000 2a/c 22 Blood T ND ND ND (-) ND ND
EUI CIC 52 F - - - - ND ND ND (-) ND ND
CI CIC 60 M 720 000 1a 18 IVDU (-) (-) 7(T8) (-) ND ND
EUI CIC 61 F - - - - (-), bgd (-), bgd (-), bgd (-) ND ND
CI CIC 64 M 1 080 000 1b ND Unknown (-) (-) (-) 81 ND ND
EUI CIC 65 F - - - - (-) (-) (-) (-) ND ND
*: Chronically HCV-infected subjects (CI); Exposed uninfected partners of chronically infected individuals (EUI).
**: Viral load expressed as LU per mL; Duration of HCV infection in years; Blood T blood transfusion, IVDU intravenous drug users.
** (-) = absence, or xx = presence of antigen-specific proliferation. The number xx stands for specific to control antigen ration, and (T4) or (T8) for the nature of
the proliferating lymphocyte population.
***(-) = no antigen specific ELISPOT; xx = presence of antigen specific ELISPOT. The number stands for specific antigen to control ratio.
Abbreviations: bgd background proliferation without antigen. ND Not determine.
The CEF panel of EBV, CMV and Flu peptides is described in ref 12.
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Figure 2 example of proliferation for PBMC of the chronically infected CIC 38 volunteer. Dot-plots show the percentage of proliferative
CD8 + (FL1/FL4) or CD4 + (FL1/FL5) - T cells. The number in the upper left panel stands for the percentage of CD4+ or CD8+ proliferative cells
among the total CD4+ or CD8+ -T lymphocyte population, respectively, in the absence (DMSO) or the presence of Core, NS3 or CEF antigens.
The positive responses are in bold characters.
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The frequencies of elispot response to Core were
higher in the CI group compared to UI no risk (p =
0.04) and to UI at risk (p = 0.04). The frequencies of
response to NS3 were higher in the CI group compared
to UI no risk (p < 0.03) and to UI at risk (p < 0.03)
(Table 1).
CEF-specific responses
EBV, CMV and Flu are viruses commonly encountered
by humans. They encode peptides corresponding to CD8
class I restricted epitopes. A CEF panel of MHC class I
restricted viral peptides presented by the most common
Caucasian HLA types has been described [12]. CEF
represents a unique peptide pool that can be used as a
positive control of antigen specific T-cell receptor-driven
activation in both Elispot and proliferation assays.
Twenty-four of the 62 uninfected (UI) volunteers
tested (39%) were positive for proliferation, including
14/32 volunteers at risk (44%) and 10/30 volunteers
without any known risk of exposure (33%) (Table 1).
For 23 volunteers the CEF-specific proliferation involved
the CD8 population, and for 1 (EFS 12) both CD4 and
CD8 populations (Tables 2 and 3). An example of CD8
response is shown in Figure 1 (panel F).
In sixteen chronically infected (CI) subjects tested,
CEF-specific proliferation was detected in 56% (9/16)
individuals (Table 1). The response was detected within
the CD8 lymphocyte subset only (Table 4). Proliferation
profile demonstrated by volunteer CIC38 is given as an
example (Figure 2, panel H).
Five of the 17 (29%) exposed uninfected (EUI) subjects
(associated with the chronically infected individuals)
tested were positive, the response also being solely by
CD8 T cell population (Tables 1 and 4).
A high spontaneous background involving CD4 or both
CD4 and CD8 subpopulations was observed for 8/62 unin-
fected (UI), 2/16 chronically infected (CI), and 4/17
exposed but uninfected (EUI) subjects (Tables 2, 3 and 4).
In case of sufficient number of cells, CEF-specific
responses were assessed also by IFN-g Elispot. IFN-g
response to stimulation with CEF pool was detected in
53% (31/58) of uninfected (UI) volunteers, namely in
60% (18/30) of subjects at risk and 46% (13/28) indivi-
duals with no known risk of HCV exposure. Similarly,
50 and 55% response to CEF was detected respectively
among chronic HCV (CI) carriers (3/6) and their unin-
fected (EUI) partners (6/11; Table 1). In summary, a
high proportion of individuals in each of the groups
tested positive for a CEF-specific response.
No statistical difference was seen in the frequency of
CEF-specific responses registered by either proliferation
or Elispot (all p values > 0.05). This reflected similar
antigen-specific T-cell receptor driven T cell activation
by HCV-unrelated antigens in all groups.
Discussion
We have studied three groups that differed with respect
to the degree of exposition to HCV: 1) chronic HCV
carrier (CI); 2) individuals who remained noninfected
despite repeated exposure through sexual contact con-
tact with these carriers (EUI); 3) healthy apparently
unnexposed volunteers (UI). Specific cellular immune
responses against HCV Core or NS3 were assessed by
Elispot or T cell proliferation assays.
The highest proportion of HCV-specific response was
observed among chronically-infected subjects (Table 1).
The fact that such a response was detected in less than
half of the patients is in agreement with previous reports
on HCV T-cell responses in chronic HCV infection [13].
Elispot responses were detected the most frequently (in 8/
20 chronically-infected volunteers tested for Core, and in
2/6, tested for NS3 responses) whereas only few chroni-
cally-infected individuals presented Core or NS3-specific
proliferative reactions (3/17, and 2/16, respectively).
The synthetic peptides used to screen cellular
responses to HCV represent sequence of HCV genotype
1 since the majority of individuals were infected by a gen-
otype 1 virus. Two of the three chronically-infected sub-
jects who gave positive NS3- responses were infected
with a genotype 1 virus. Seven of the eight chronically-
infected subjects who were positive for Core by the
Elispot assay, were also infected by HCV genotype 1.
Meanwhile, chronically-infected patients carried also
HCV of three other genotypes: one was infected by a
genotype 2 virus, and two by each of genotypes 3 and 4
(Table 4). Very low frequency of NS3-responders
amongst patients infected with HCV genotype 2, 3 or 4,
may reflect a limited number of non-HCV genotype 1
infected individuals included in this study and also the
genotype variation of NS3 sequence. The latter explana-
tion is, however, hardly applicable for the core-specific
responses, since HCV core is highly conserved with very
few amino acid inter-genotype differences [14].
The low frequency of proliferative responses compared
to Elispot could be attributed to a higher sensitivity of the
latter (assay). However, in our view, decisive is the type of
the registered response. Elispot assays performed with ex
vivo isolated PBMC preferentially detect effector lympho-
cytes that do not need to expand, while assays using in
vitro expanded T lymphocytes rather detect precursors of
memory T cells with a proliferative capacity [15]. The low
frequency of proliferative responses among chronic HCV
carriers may rather reflect a weak HCV memory response
(specifically when comparing chronic hepatitis C patients
to those resolving HCV infection; for review, 13). Of parti-
cular note, relatively few individuals gave a concomitant
positive response in both assays. This absence of correla-
tion between Elispot and proliferative responses in chroni-
cally-infected individuals suggests that effector and
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memory T cells are distinct T cell populations, probably
recognizing different epitopes. Such phenomenon was
described earlier [16].
Interestingly, HCV Core-specific Elispot responses
were observed in a relatively high proportion (30%) of
the uninfected partners of chronically-infected indivi-
duals (Table 1). This is in agreement with previous
reports on the populations of uninfected seronegative
individuals exposed to HCV, including healthy relatives
of HCV-infected individuals, intravenous drug users, and
individuals with occupational exposure [17-21].
The most striking result of the current study was that
despite stringent criteria of the positive cellular response,
an HCV-specific response was registered in 20% of unin-
fected subject tested (13/65; Tables 2 and 3). This group
was split into two subgroups, depending on the possibility
of exposure to HCV. Indeed, eight individuals who dis-
played a positive result could have been exposed to HCV
(professionally), although there was no clear history of
contamination (Table 3). No such risk was, however, iden-
tified to explain positive results in the remaining five indi-
viduals (Table 2).
The detection of HCV specific cellular responses in
uninfected volunteers reflects the difficulty to precisely
identify all (possible) risks of exposure to HCV. Further-
more, it may also reflect a past inapparent HCV infection.
Clearance of HCV viremia associated with cellular immu-
nity in the absence of seroconversion has been reported in
populations at risk for HCV exposure [5,22,23].
Other causes for detecting HCV-response in healthy
risk-free individuals cannot be categorically ruled out.
Two uninfected volunteers had positive proliferative
response for Core: one with no risk of exposure to HCV
(EFS 20) gave a response that involved both CD4 and CD8
populations, whereas the other that only implicated a CD4
population response (EFS 11) was retrospectively shown
to have been exposed to HCV. For EFS 20, we could map
the reactive sequence to Core amino acid residues 173-
190 (not shown). An extensive sequence search using the
BLAST tool [24] revealed a eight amino acid homology
between HCV Core 174-185 (FSIFLLALLSCL) and HBs
antigen 41-52 (FIIFLFXLLXCL). While it remains possible
that the observed reactivity corresponds to a cross-reactive
immunization [8-10], it is noteworthy that EFS 20 was
neither infected nor immunized with HBV.
NS3-specific proliferative responses were observed in
four uninfected volunteers (COC 13, and EFS 14, 21
and 24). The PBMC of these individuals were also reac-
tive to the CEF peptides including 12 influenza epitopes.
As immunization against Influenza virus neuraminidase
was reported to generate immune responses crossreac-
tive with HCV NS3 [10], we cannot formally exclude
that T-cell proliferation in response to NS3 resulted
from cross-reactivity.
In all three groups, a much higher proportion of indivi-
duals tested positive for CEF-specific response registered
by Elispot and proliferation tests. The proportion of
responders (number of positive/total number tested)
varied between groups, but was within the limits of
stochastic variations: between 56% (9/16) for the chroni-
cally-infected subjects and 29% (5/17) for their unin-
fected partners (in proliferation). These figures matched
the range of proportions seen in CEF-positive Elispots:
60% (18/30) for at risk uninfected volunteers and 46%
(13/28) for uninfected volunteers with no known risk of
HCV-exposure (Table 1). This was somewhat lower that
the data reported by Currier et al. [12], but similar to
that reported by Horton et al. [25] possibly reflecting the
heterogeneity of the HLA alleles in the studied groups.
All CEF-specific proliferative responses involved the CD8
subpopulation, and in 1 of 95 individuals, both the CD8
and CD4 compartments. This is not surprising since
most of the CEF peptides were 8 to 9 mers representing
CD8 class I-restricted epitopes, although CD4-specific
cytotoxic responses have also been reported in human
viral infections [26-28].
As there were no statistical difference between the
groups in the frequencies of proliferative or Elispot
responses to the control (CEF) antigens (Table 1), expo-
sure to or infection by HCV did not seem to have any
major impact on the frequency of cellular responses to
unrelated viruses. Hence, it is unlikely that the number of
positive cellular responses to HCV antigens could be
explained by antigen stimulation(s) specific to other viral
antigens. In addition, pair-wise comparisons revealed no
difference in the occurrence of cellular immune response
against HCV core and/or NS3 among CEF-negative versus
CEF-positive individuals in any of the groups (UI with
known risk, UI at risk, EUI, or CI; all p values > 0.3). Thus,
there is no evidence demonstrating that anti-CEF cellular
reactivity interfere with the detection of anti-HCV cellular
responses.
Alternatively, atypical HCV-specific immune responses
may be generated by the occult HCV infections of the
liver [29]. Such infections have been described for patients
with abnormal liver function of unknown origin, who pre-
sent negative HCV PCR and Elisa results in the serum but
where HCV RNA is detected in the liver [30]. However, in
our study, all uninfected CIC volunteers had normal liver
biology. For the twenty COC individuals, liver function
was investigated using the Fibrotest [31], and all gave a
normal value (not shown). Thus, it is likely that, in this
study, the detection of a positive HCV-specific cellular
response did not reflect an occult HCV infection.
The polymorphism of the IL28B gene has been recently
associated with both spontaneous resolution of HCV
infection and sustained virologic response in pegylated
interferon/ribavirin treated patients [32-34]; we can
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speculate that such a polymorphism may explain partially
our results but this study was initiated before the first
report and we are unauthorized to make a retrospective
genetic study.
In summary, the detection of HCV-specific immune
responses in uninfected volunteers may reflect an under-
estimated prevalence of inapparent and resolving acute
HCV infections. This changes our understanding of the
epidemiology and the physiopathology of HCV infection.
An alternative, not mutually exclusive, hypothesis is the
existence of cross-reactivity between HCV antigens and
other viral or common antigens present in the general
population, as previously suggested by other researchers.
Patients and methods
Patients and volunteers
Sixty-five presumably unexposed and uninfected volun-
teers (Uninfected individuals, UI) were studied. All
volunteers were negative in HCV PCR assay (ABBOTT
Real Time HCV, Abbott, Rungis, France, threshold < 12
I.U/ml) and had a negative HCV-specific humoral
response according to a commercial Elisa assay (MONO-
LISA anti-HCV Plus V2, Biorad, Marnes-la-Coquette,
France). This enzyme immunoassay contains HCV
recombinant proteins expressed in E coli including
sequences from NS3 and NS4 and from the structural
core protein. All volunteers were not infected by HBV or
HIV. These volunteers were categorized according to the
putative risk of exposure to HCV [no known risk (n =
33), Table 2; at risk (n = 32), Table 3]. Exclusion factors
for exposure to HCV [11] were: professional exposure,
drug abuse, blood transfusion or injection of blood pro-
ducts, sexually transmitted diseases, incarceration, alco-
holism, dialysis, endoscopy, acupuncture, mesotherapy,
invasive cosmetic treatment, piercing, tattooing, sexual
exposure, familial exposure, and hospitalization or outpa-
tient treatment in a developing country. The 65 volun-
teers were recruited in three distinct centers located in
the Paris area. Initialy enrolled was a group of 20 unin-
fected volunteers [mean age: 46 year; range: 27-65; sex
ratio: 1] (Necker Clinical Investigation Center, CIC
volunteers). However, it was retrospectively reported that
fifteen individuals from this group might have been
exposed to HCV due to their occupational status. A sec-
ond group of 25 volunteers was recruited at a french
blood center in Paris (Etablissement Français du Sang
(EFS), Paris; EFS 01 to 25). This group comprised 8
volunteers without any known risk for exposure to HCV
[mean age: 27.8 year; range: 18-40; sex ratio: 0.14] and 17
volunteers at risk [mean age: 43.1 year; range: 21-64; sex
ratio: 0.13]. The third group of 20 volunteers with no
known risk for exposure to HCV was recruted at the
Center for clinical investigation of the Cochin Hospital,
Paris [COC 01 to 20; mean age: 27.4 year; range: 18-41;
sex ratio: 1.2].
Twenty chronic HCV infected carriers and their
exposed uninfected sexual partners were included as
positive controls for HCV infection and potential expo-
sure, respectively (Table 4). Infected patients [mean age:
46 year; range: 24-66; sex ratio: 1] were all HCV seroposi-
tive and viraemic. All viruses were genotyped except for
one volunteer; the HCV genotypes were: 1b (n = 10), 1a
(n = 4)], 2a/c (n = 1), 3 (n = 2), and 4 (n = 2). The mode
of contamination was established for fifteen individuals;
ten were infected by blood transfusion, one after surgery,
one following a tattooing procedure, and three were
intravenous drug users. The 20 exposed uninfected part-
ners [mean age: 44 year; range: 26-63; sex ratio: 1] were
active sexual contacts (> 2 years) of these infected HCV
carriers. All exposed uninfected individuals were HCV
seronegative and HCV-RNA negative by PCR.
None of the volunteers was infected by HIV, and all
had a normal blood cell count the day of harvesting
PBMCs. Biomedical research was approved by the local
ethics committee (RBM 01-24), and was carried out in
accordance with the Helsinki Declaration.
Preparation of PBMC
PBMCs were isolated from heparinized blood as
described [35]. The PBMCs were frozen at -80°C in 90%
fetal calf serum (D. Dutscher, Strasbourg, France) con-
taining 10% DMSO (Pierce, ThermoFisher, Brebières,
France), and stored in liquid nitrogen until used.
Synthetic peptides
The consensus sequence of the Core protein (genotype 1a)
was covered by thirty-seven 15 mer peptides that over-
lapped by 10 residues, as described [35]. NS3 [consensus
1b, aa 1027-1657] was represented by sixty-eight overlap-
ping 15 mer peptides corresponding to regions encoding
the CD4 and CD8 epitopes were used. These clusters of
T4 and T8 epitopes corresponded to the following regions:
aa 1072-1111 (TCVN... LVGW); 1167-1191(GPLL...
GVAK); 1199-1355(SMET... TDAL); 1461-1475 (TVDF...
IETT); 1531-55(TPAE... QDHL); 1576-1652(TQKA...
ACMS), according to the Los Alamos databases [36,37]. A
pool of unrelated 12-to 15-mer peptides derived from Gag
and Nef of simian immunodeficiency virus (SIVmac239)
were used as a negative control. Core and SIV peptides
were purchased from NeoMPS (Strasbourg, France), and
NS3 ones from Proimmune (Oxford, UK). Each peptide
was certified to be > 80% pure, by RP-HPLC. Positive con-
trol was a pool of 32 peptides (CEF) corresponding to
well-characterized CD8 class I restricted epitopes of
human cytomegalovirus (CMV), Epstein-Barr virus (EBV)
and Influenza virus [12]. CEF pool was obtained through
the NIH AIDS Research and reference reagent program,
or Anaspec Inc., San Jose, CA, USA. The peptides were
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dissolved in DMSO at 1 mg/ml, and were stored at -80°C
until used.
Immunological assays
Virus-specific circulating effector T lymphocyte
responses were studied using two distinct functional
assays:
Elispot assay HCV-specific T cell responses of freshly
isolated or frozen PBMC were studied by ex vivo ELISPOT
assays [38], using the panels of Core or NS3 peptides
described above. Peptides were used at a final concentra-
tion of 1 μg/ml. Negative controls consisted of cells incu-
bated in medium. Phorbol myristate acetate and
ionomycin (25 and 100 ng/ml, respectively; Sigma-Aldrich
Chimie, Saint-Quentin Fallavier, France) were used as
positive controls. The frequencies of IFN-g producing cells
were expressed as the number of spot-forming cells (SFC)
per 106 cells. Frequencies lower than 50 spots/l million
PBMC were considered unspecific. An assay was consid-
ered positive if: 1/. The number of spots generated in
response to stimulation with specific peptides exceeded
the mean of the number of spots obtained with culture
medium plus 2 SD; and 2/. Its ratio to the number of
spots with culture medium was > or = 4.
Proliferation assay PBMC (2 ×106/ml) were labelled with
10 mM carboxyfluorescein diacetate succinimidyl ester
(CFDA-SE; Invitrogen, ref C1157) in serum-free medium
for 30 min at 37°C [39]. Labeled PBMC were washed with
complete medium (D-MEM +1% non essential aminoacids,
1 mM L-glutamine, Invitrogen, Cergy, France) supplemen-
ted with 10% heat inactivated human AB serum (SAB, Bio-
west, France), and incubated in complete D-MEM culture
medium at 37°C under 5% CO2. The following antigen sti-
mulations were performed: 1/. HCV-specific with pools of
Core or NS3-specific peptides each at a final concentration
of 1 μg/ml; 2/. Common antigen-specific CEF peptides as
positive control (final concentration 0.5 μg/ml); 3/. Mito-
gen (superantigen) Staphylococcus Enterotoxin B (Ref
S4881, Sigma, St Louis, MI) at 500 ng/mL as positive con-
trol for PBMC viability; 4/. An irrelevant SIV-peptide pool,
and complete medium plus 0.05% DMSO (peptide diluent)
as negative controls.
After 6 days incubation, cells were washed in PBS and
incubated for 30 min at 25°C with anti CD3 phycoery-
thrin-Texas Red (ECD)-, anti-CD8b phycoerythrin-cyanin
5 (PCy5)-, and anti CD4 phycoerythrin-cyanin 7 (PCy7)-
conjugated monoclonal antibodies (refs A07748, 6607101,
and 737660 from Beckman-Coulter respectively). At the
end of the incubation period, cells were washed twice in
PBS and fixed with 200 μL of 2% formaldehyde solution in
PBS for 15 min at 25°C. Cell division accompanied by
CFSE dilution [39] was analyzed by flow cytometry. For
each sample, at least 105 events were acquired using a
FC500 cytometer (Beckman Coulter). Data were analysed
with FlowJo (TreeStar). Lymphocytes were gated based on
their forward and side scattering dot plot. T lymphocytes
were defined based on their expression of CD3 and CD4
or CD8. The following criteria for antigen-specific prolif-
eration were set: 1/. Background of proliferation without
antigen (DMSO) < 4%; 2/. Antigen proliferation ratio
(Antigen/SIV) > or = 4.; 3/. Absolute number of proliferat-
ing cells (i.e. CFSE negative) > 100; 4/. Threshold value >
mean of difference between control antigen (SIV) + 2 SD.
Statistics
Frequencies of HCV-specific proliferative and IFN-g
ELISPOT responses between groups were compared
between the groups pairwisely using two-sided t-test for
independant samples assessing difference in proportions.
Tests were done using Quick Calcs, Graph Pad
Software.
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